Study of S-1 in Combination With Radiotherapy in Esophageal Cancer
This trial aims to study the safety, the local control, and the overall survival of S-1 combined with radiotherapy for patients with esophageal squamous cell carcinoma. 105 patients will be recruited into this trial.
Esophageal Squamous Cell Carcinoma
DRUG: S-1|RADIATION: Radiation therapy
Number of participants with adverse events, 1 years|3-yr local control rate, 3 years
Overall survival, 3 years
This trial aims to study the safety, the local control, and the overall survival of S-1 combined with radiotherapy for patients with esophageal squamous cell carcinoma. 105 patients will be recruited into this trial.